For IV use only. Granulocyte counts should be ≥1,500 cells/mm
3. Discontinue use if extravasations occur. Close haematological monitoring should be undertaken. Delay treatment if neutrophil count is <1,500/mm
3 &/or platelet count is <75,000/mm
3. Not to be given concomitantly w/ radiotherapy if the treatment field includes the liver. Avoid contact w/ the eyes. History of ischemic cardiac disease. Investigation should be carried out if patient presents signs or symptoms suggestive of infection. Frequently monitor myelosuppression during & post-therapy. Promptly evaluate patients w/ alterations in baseline pulmonary symptoms or new onset of dyspnoea, cough, hypoxia. May cause severe constipation eg, paralytic ileus. Compromised bone marrow reserve prior to irradiation/chemotherapy or recovering from effects of previous chemotherapy. History or preexisting neuropathy. May affect ability to drive or operate machinery. Reduce dose in patients w/ severe hepatic impairment.
Sign Out
